| DCC4878 |
Sr8185 |
Novel Selective TBK1/IKK dual inhibitor with anticancer potency |
|
| DCC4879 |
Srctide |
Peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR) |
|
| DCC4880 |
Srebp-in-dhg |
Novel inhibitor of sterol regulatory element-binding protein (SREBP), impairing the SREBP activity by inhibiting glucose transporters and thereby activating AMP-activated protein kinase (AMPK) |
|
| DCC4881 |
Sri-22138 |
Novel mixed μ opioid receptor (MOR) agonist and δ/κ opioid receptor (DOR/KOR) antagonist |
|
| DCC4882 |
Sri-29132 |
Highly blood-brain barrier permeant, potent, and selective for LRRK2 kinase activity, being effective in attenuating pro-inflammatory responses in macrophages and rescuing neurite retraction phenotypes in neurons. |
|
| DCC4883 |
Sri-31040 |
Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding |
|
| DCC4884 |
Sri-35241 |
Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv) |
|
| DCC4885 |
Sri-36160 |
Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells |
|
| DCC4886 |
Sri-37683 |
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
| DCC4887 |
Sri-37684 |
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
| DCC4888 |
Sri-39067 |
Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice |
|
| DCC4889 |
Srt3025 |
Novel Sirtuin1 Activator, Down-Regulating Sclerostin and Rescuing Ovariectomy-Induced Bone Loss |
|
| DCC4890 |
Srt3025 Hydrochloride |
Novel potent SIRT1 activator |
|
| DCC4891 |
Srt3190 (2s,3r) |
Novel selective CXCR2 antagonist |
|
| DCC4892 |
Srta-in-i |
Novel potent inhibitor of Staphylococcus aureus sortase A (SrtA) |
|
| DCC4893 |
Ss1020 |
Novel antiestrogen, lacking estrogenic and genotoxic actions |
|
| DCC4894 |
SS-amyloid-in-7l |
Potent ß-amyloid aggregation inhibitor; Antioxidant |
|
| DCC4895 |
SS-carboline-1-carboxylic Acid |
Potent competitive inhibitor of indoleamine 2,3-dioxygenase (IDO) |
|
| DCC4896 |
SS-cit |
Non-selective potent dopamine reuptake inhibitor |
|
| DCC4897 |
SS-cit Tartrate |
Non-selective potent dopamine reuptake inhibitor |
|
| DCC4898 |
SS-elemene |
Novel inhibitor of Pak1 activation, anti-cancer ingredient isolated from the Chinese traditional herb Curcuma wenyujin |
|
| DCC4899 |
SS-hydroxymethyl Chalcone |
The first selective inhibitor of Histone Deacetylase 2 (HDAC2) |
|
| DCC4900 |
Ssj-183 |
Novel antimalarial agent |
|
| DCC4901 |
SS-lysine |
Elongation factor P (EF-P) fuction modifier |
|
| DCC4902 |
Ssm3 Tfa Salt |
Potent furin inhibitor, blocking furin-dependent cell surface processing of anthrax protective antigen-83 in vitro. |
|
| DCC4903 |
SS-nf-atra |
Novel chimeric degrader against cellular retinoic acid binding proteins (CRABPs), inducing the AhR-dependent degradation of CRABP-1 and CRABP-2 via the ubiquitin-proteasome pathway |
|
| DCC4904 |
SS-nf-jq1 |
Novel chimeric degrader against bromodomain-containing (BRD) proteins, inducing the interaction of AhR and BRD proteins and displaying effective anticancer activity that correlated with protein knockdown activity |
|
| DCC4905 |
SS-nicotinamide Adenine Dinucleotide, Reduced Disodium |
Cofactor for mitochondrial deacetylase sirtuin-3 enzyme, regulating energy metabolism and immunity and modulating inflammasome assembly |
|
| DCC4906 |
Ssr126768a |
Novel Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor |
|
| DCC4907 |
Ssr180575
Featured
|
SSR-180,575 is a drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO. It has been shown to have neuroprotective and cardioprotective effects and to stimulate steroidogenesis of pregnenolone in the brain, which may be linked to its neuroprotective action. |
|
